På tide å se litt tilbake på historien. Husker dere dette som ble sagt Q2 2017:
« SAN HQ was launched as planned at the Annual meeting of the American Society of Gene and Cell Therapy. A meeting attended by all key players and innovators in the gene therapy segment. For ArcticZymes the conference was fruitful to introduce the benefits SAN HQ can offer in the research, development and manufacturing of viruses utilized in gene therapy. Over 20 companies from all geographical regions expressed a keen interest in exploring the uniqueness’s of SAN HQ and customer evaluations have been initiated.»
Dette ble senere sagt Q3 2018:
« Several customers have already transitioned towards placing orders for the larger bulk package size of SAN-HQ. ArcticZymes anticipates that approximately 10-20 customers will lock down their large-scale cGMP manufacturing processes with SAN-HQ over the next 3 years. Expected average annual sales will range between 1-3 MNOK depending on the customers manufacturing process and nature of the therapeutic agent»
Folk begynte da å regne litt. Det er dette vi ser så smått begynne materialisere seg i dag. Holter holder hva han sier.
